Debates of April 10th, 2024

Questions Passed as Orders for Returns

[Kevin Lamoureux, Liberal, Parliamentary Secretary to the Leader of the Government in the House of Commons]

Mr. Speaker, furthermore, if the government's responses to Question Nos. 2356, 2358 to 2360, 2362 and 2364 to 2370 could be made orders for returns, these returns would be tabled in an electronic format immediately.

[The Deputy Speaker, Conservative, Chris d'Entremont]

Is that agreed?

[Some hon. members]

Agreed.

Question No.2356—

[Julie Vignola, Bloc, Beauport—Limoilou, QC]

With regard to all federal contracts awarded between 2019 and 2023 to suppliers of the federal government, reporting departments, organizations and agencies, federal offices and any other federal entity that received funds from the Public Accounts of Canada: (a) which contracts required essential knowledge of the English language, both with respect to the spoken or written language of suppliers in the workplace and the language of deliverables; and (b) what are the details of each contract in (a), including the (i) contract number, (ii) name of the supplier, (iii) name of the federal department or agency responsible for the contract, (iv) amount awarded, (v) date of the contract, (vi) languages required for the work, (vii) languages required for deliverables, (viii) justification for requiring only English as the language of work or deliverables?

(Return tabled)

Question No.2358—

[Lori Idlout, NDP, Nunavut, NU]

With regard to all federal funding committed to the creation and maintenance of housing stock in Nunavut, broken down by fiscal year since 2015-16: (a) what is the total amount committed; (b) what is the total amount spent; (c) how much new housing stock was created in Nunavut; and (d) what are the government's projections for the number of housing units that will be built in Nunavut by 2030?

(Return tabled)

Question No.2359—

[Branden Leslie, Conservative, Portage—Lisgar, MB]

With regard to the Cadets and Junior Canadian Rangers youth programs, in the 2022-23 fiscal year: (a) how many staff, broken down by employment status (i.e. full-time, part-time), were employed at the (i) Regional Headquarters, including the Northwest Region, Pacific Region, Central Region, Eastern Region, Atlantic Region, (ii) National Headquarters, (iii) Corps/Squadron level; (b) of the staff in (a), what were their roles, responsibilities, and job descriptions; (c) what was the salary range of those in (a)(i) and (a)(ii); (d) what professional and special services were used, how often, and for what purpose, and how much did each of these items cost; (e) how much money was spent on advertising by the (i) National Headquarters, (ii) Northwest Region, (iii) Pacific Region, (iv) Central Region, (v) Eastern Region, (vi) Atlantic Region; and (f) what is the breakdown of (e) by type or platform of advertising (e.g. Meta, Google, local television, local newspapers), how much money was spent exclusively on recruitment efforts, and what did those efforts include?

(Return tabled)

Question No.2360—

[Branden Leslie, Conservative, Portage—Lisgar, MB]

With regard to the federal public service, broken down by year since 2015: (a) how many public servants are employed in each department, agency, Crown corporation, or other government entity; (b) what is the breakdown of the employees in (a) by (i) branch of each department, agency, Crown corporation, or other government entity, (ii) directorate in each branch; (c) what is the breakdown of the employees in (a) and (b) by level (i.e. at the executive level or higher, below the executive level); and (d) what is the breakdown of employees in (a) through (c) by employment status (i.e. full-time, part-time)?

(Return tabled)

Question No.2362—

[Philip Lawrence, Conservative, Northumberland—Peterborough South, ON]

With regard to government programs that provide funding for roads and highways, including both regular and non-traditional highways or roads, such as those in northern or remote areas: what are the details of all funding agreements that are currently in place, including, for each, the (i) amount of federal funding, (ii) type of agreement, (iii) partners of the agreement, (iv) cost-sharing arrangement, (v) name of the agreement, (vi) program under which the funding is provided, (vii) project description, (viii) specific geographic location of the roads receiving the funding, including highway or road numbers, if applicable?

(Return tabled)

Question No.2364—

[Gord Johns, NDP, Courtenay—Alberni, BC]

With regard to contracts awarded since the 2009-10 fiscal year, broken down by fiscal year: what is the total value of contracts awarded to (i) McKinsey & Company, (ii) Deloitte, (iii) PricewaterhouseCoopers, (iv) Accenture, (v) KPMG, (vi) Ernst and Young, (vii) GC Strategies, (viii) Coredal Systems Consulting Inc., (ix) Dalian Enterprises Inc., (x) Coradix Technology Consulting Ltd, (xi) Dalian and Coradix in joint venture?

(Return tabled)

Question No.2365—

[Colin Carrie, Conservative, Oshawa, ON]

With regard to Health Canada’s approval of the COVID-19 modRNA vaccines (modified with N1-methylpseudouridine) for pregnant women: (a) what specific research data supported the claims that (i) this product may be safely administered at any stage of pregnancy, (ii) this product protects pregnant women from SARS-CoV-2 infection and severe disease, (iii) the vaccinated mother is less likely to transmit SARS-CoV-2 to her newborn after delivery compared to an unvaccinated mother, (iv) the modRNA vaccine, and consequently the spike protein, do not excrete into breast milk, (v) the modRNA, and consequently the spike protein, do not cross the placental barrier, (vi) all modRNA is destroyed in the human body within about two days, (vii) there is no possibility that the modRNA vaccine contents will enter the cell nucleus and modify the human genome; (b) with respect to the claims in (a), has Heath Canada modified these claims based on updated scientific research, and if so, which claims and how; (c) what is the real-world data indicating that this product presents no safety concerns for the pregnant woman or the developing fetus or newborn; (d) what is the quantitative threshold for a concerning safety signal for these cohorts; (e) how has the monograph for the COVID-19 modRNA vaccines been updated in relation to pregnancy and lactation to convey this safety research data; and (f) when were these updates made?

(Return tabled)

Question No.2366—

[Cathay Wagantall, Conservative, Yorkton—Melville, SK]

With regard to Health Canada’s (HC) approval of mRNA vaccines for pregnant and lactating women, and children, youth, and adults of reproductive age: (a) what is the cause of the reported menstrual irregularities in vaccinated women; (b) what is the safety data on any single exposure and repeated exposure to lipid nanoparticles (LNP) for (i) pregnant women, (ii) unborn fetuses; (c) do LNPs, spike protein encoding mRNA, or spike protein pass through the placenta; (d) if the answer to (c) is affirmative, does this present a safety concern to the unborn fetus, and how was this determined; (e) where are LNPs, mRNA, or spike protein distributed in the fetus; (f) what are the potential genetic effects of the COVID-19 vaccine with respect to the epigenetic effects on germ cells; (g) what are the specific references confirming that mRNA is not integrated into the genome or genetic material of the oocyte or the sperm; (h) how, and for how long, does HC actively monitor or plan to actively monitor the impact of the dose-dependent effect of the vaccine on future fertility in (i) vaccinated women and men of child-bearing age, (ii) vaccinated children, (iii) children exposed in utero to the COVID-19 vaccines following maternal injection; (i) does HC actively monitor or plan to actively monitor the adverse effects of the mRNA vaccination, and for how long, in the (i) pregnant mother, (ii) fetus; (j) if the answer to (i) is affirmative, does this or will this include miscarriages, uterine deaths, possible illnesses and birth malformations; (k) with respect to studies analyzing various components and products of COVID-19 vaccination, including spike protein, what have been the findings comparing placental tissue and breast milk from vaccinated and non-vaccinated mothers, and what are the specific references; (l) based on available research and real-world data, what updated written guidance has HC provided to provinces and territories regarding information which is given to pregnant women prior to and after vaccination, their doctors (neonatal doctors, paediatricians, fertility doctors, obstetricians), other medical staff (including midwives), and vaccinators with respect to (i) the potential adverse events to monitor post-injection, (ii) their duty to report adverse events and where; and (m) does the guidance in (l) include the updated mRNA vaccine monographs and where to find them?

(Return tabled)

Question No.2367—

[Lori Idlout, NDP, Nunavut, NU]

With regard to Bill C-61, An Act respecting water, source water, drinking water, wastewater and related infrastructure on First Nations land, since December 7, 2022: (a) what are the details of all consultations for the purposes of this legislation, including the (i) date of consultation, (ii) name of the First Nations rights-holder or organization consulted, (iii) details of the feedback received; (b) how many engagements did the government receive (i) through the mail, (ii) by phone, (iii) by email; (c) did the government receive any requests to extend the consultation period; and (d) what changes were made to the draft proposal sent to First Nations rights-holders and organizations on February 17, 2023, that were reflected in the version of Bill C-61 that was introduced and read the first time on December 11, 2023?

(Return tabled)

Question No.2368—

[Scott Reid, Conservative, Lanark—Frontenac—Kingston, ON]

With regard to penitentiary farm and agriculture and agri-food operations at the Joyceville Institution and the Collins Bay Institution: (a) what funds have been spent on Public Services and Procurement Canada fees and disbursements and professional project management services, including, but not limited to, concept design, project leaders, tender packages, geo-technology, hydrogeology, engineering, and architectural consultants, broken down by fiscal year since 2018; (b) what funds have been spent on feasibility studies, public consultations, online consultations, and contracts with Goss Gilroy and Monachus Consulting during the feasibility and consultation phase of the penitentiary farm project, between January 1, 2016 and December 31, 2018; (c) prior to the reinstatement of the penitentiary farm program, what revenues were earned by Correctional Service Canada from rental agreements for the penitentiary farmland at the Collins Bay Institution and the Joyceville Institution, broken down by year for each year from 2013 to 2018; (d) of the revenues earned from penitentiary agriculture programming since 2018, what is the breakdown by source and year; (e) how many offenders are currently employed in penitentiary agriculture programming, broken down by location; and (f) of the offenders who have been employed in penitentiary agriculture programming since it was reintroduced in 2018, how many have been released, and, of those released, how many obtained jobs in the agriculture sector?

(Return tabled)

Question No.2369—

[Maxime Blanchette-Joncas, Bloc, Rimouski-Neigette—Témiscouata—Les Basques, QC]

With regard to funding for research at universities and associated organizations: (a) what amount of funding, in Canadian dollars, is provided directly by the various federal government departments; (b) what amount of funding, in Canadian dollars, does not come from the granting agencies, used to fund research projects (i) in universities, (ii) in research organizations affiliated with universities, (iii) by researchers affiliated with a university, (iv) in total; and (c) what is the distribution of this amount in (a) and (b) between (i) U15 universities, (ii) small and medium-sized universities?

(Return tabled)